Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective

(2016) Gissette Reyes-Soffer et al.   CIRCULATION

PCSK9 Association With Lipoprotein(a)Novelty and Significance

(2016) Hagai Tavori et al.   CIRCULATION RESEARCH

From Lipids to Inflammation

(2016) Michael D. Shapiro et al.   CIRCULATION RESEARCH

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role

(2016) Frederick J. Raal et al.   JOURNAL OF LIPID RESEARCH

Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes MellitusSignificance

(2015) Esther M. Ooi et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

(2015) Rocco Romagnuolo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

(2014) Daniel Gaudet et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lipoprotein(a)

(2014) Marlys L. Koschinsky et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

(2014) E. A. Stein et al.   EUROPEAN HEART JOURNAL

Lipoprotein(a) as a therapeutic target in cardiovascular disease

(2014) Marlys Koschinsky et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

(2014) Frederick J. Raal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy

(2013) Nihar R. Desai et al.   CIRCULATION

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk

(2013) Amit V. Khera et al.   CIRCULATION

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

(2013) Tanja Kosenko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lipoprotein(a): resurrected by genetics

(2013) F. Kronenberg et al.   JOURNAL OF INTERNAL MEDICINE

Scavenger receptor-BI is a receptor for lipoprotein(a)

(2013) Xiao-Ping Yang et al.   JOURNAL OF LIPID RESEARCH

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

(2013) Maryssa Canuel et al.   PLoS One

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation

(2013) Yascara Grisel Luna Saavedra et al.   PLoS One

Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism

(2012) Alanna Strong et al.   JOURNAL OF CLINICAL INVESTIGATION

The PCSK9 decade

(2012) Gilles Lambert et al.   JOURNAL OF LIPID RESEARCH

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

(2009) Marianne Abifadel et al.   HUMAN MUTATION

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease